New drug duo aims to shrink hard-to-treat cancers
NCT ID NCT07276373
First seen Dec 11, 2025 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tests a new drug called nenocorilant combined with an immunotherapy (nivolumab) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 adults with various advanced cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGSan Antonio, Texas, 78229, United States
-
Site 02
RECRUITINGWest Valley City, Utah, 84119, United States
-
Site 03
RECRUITINGLos Angeles, California, 90025, United States
-
Site 04
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.